Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14903874 | 0.74 | — | — | |
| SCHEMBL20292477 | 0.74 | TSPO (0.45) | TSPOLMNATP53ALOX15SMN1; SMN2 | |
| SCHEMBL1617437 | 0.73 | TLR4 (0.49) | LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12296371 | 0.72 | MCL1 (0.45) | TSPOLMNATP53ALOX15SMN1; SMN2 | |
| SCHEMBL11738399 | 0.72 | MAPK1 (0.33) | TP53 | |
| SCHEMBL480709 | 0.71 | TSPO (0.43) | TSPOLMNATP53ALOX15SMN1; SMN2 | |
| SCHEMBL29264295 | 0.71 | SIRT1 (0.31) | — | |
| SCHEMBL11782843 | 0.70 | CYP1A2 (0.38) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9839274 | 0.68 | BCHE (0.38) | TSPOLMNAALDH1A1KDM4E | |
| SCHEMBL1053598 | 0.68 | BCHE (0.50) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552891-B1 | TRICYCLIC INDOLE DERIVATIVES AS PBR LIGANDS | GE HEALTHCARE LTD (GB) | 2018-08-08 | — | — | EP | disclosed |
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-9314541-B2 | In vivo imaging method for cancer | GE HEALTHCARE LIMITED (GB) | 2016-04-19 | — | — | US | disclosed |
| US-9220795-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2015-12-29 | — | — | US | disclosed |
| US-9168317-B2 | In vivo imaging method of mood disorders | GE HEALTHCARE LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| US-20140364615-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8790619-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| EP-2621544-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE Healthcare UK Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| US-8501153-B2 | Active enantiomer | GE HEALTHCARE LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8501153-B2 | Active enantiomer | GE HEALTHCARE LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2013-07-18 | — | — | US | disclosed |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012041953-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012038532-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-2411362-A2 | INDOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20120020884-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| WO-2011117421-A1 | TRICYCLIC INDOLE DERIVATIVES AS PBR LIGANDS | GE HEALTHCARE LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GE HEALTHCARE LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GE HEALTHCARE LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020884-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | TSPO 50/4885LMNA 2612/4885TP53 3202/4885 |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | MKI67, PBRM1, BRD4 | TSPO 13/4885LMNA 3416/4885TP53 575/4885 |
| US-20110070161-A1 | ACTIVE ENANTIOMER | GABRA5, GABRP, GABRA4 | TSPO 9/4885LMNA 3965/4885TP53 4326/4885 |
| US-20140364615-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | TSPO 50/4885LMNA 2612/4885TP53 3202/4885 |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | SLC18A2, SLC6A2, SLC6A4 | TSPO 72/4885LMNA 2390/4885TP53 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.